the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer: A Single-arm, Multi-center, Open-label Clinical Study
Latest Information Update: 29 Jul 2025
At a glance
- Drugs Sacituzumab Tirumotecan (Primary) ; Tislelizumab (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 29 Jul 2025 New trial record